Reprogramming the Microbiome: Engineering Phage-Resistant LBPs for Durable Therapeutic Impact

12:00 pm - Thursday 29th January 2026

  • Demonstrate how CRISPR-enhanced bacterial strains resist phage attack to improve engraftment and therapeutic persistence
  • Leverage virome analysis to uncover viral drivers of LBP failure across women’s health and gut indications
  • Expand platform applications from vaginal microbiome to gut disorders, showcasing data from preclinical developments

Speakers:

Chief Technology Officer
Ancilia Biosciences